2017-CA-001766 (Fritz Gray, Maney & Gordon, P.A.)
When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
But its still wildly difficult for most of us to walk away from, say, a warm cookie or a juicy cheeseburger
Its best to speak with our Ohio GLP-1 lawsuit attorneys as soon as possible to assess your eligibility
Dulaglutide was less studied but showed promising signs in animals, increasing beneficial bacteria like Bacteroides, Akkermansia, and Ruminococcus